Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacodynamics cell proliferation

The usual GLP 30- or 60-day repeat-dose toxicology study with a recovery group offers an opportunity to perform a more systematic investigation of the more subtle pharmacodynamic or toxicologic effects of biopharmaceuticals than those endpoints usually incorporated into such protocols. Some of these demand tissue samples, but many involve noninvasive biomarkers that can be carried forward into early phase human studies. These might include CNS assessments, inflammation and immune activation or suppression, cell proliferation or apoptosis in tissue samples, and end-organ toxicities. [Pg.321]

Jusko (4, 5) described pharmacodynamic (PD) models for cell proliferation and irreversible effects of chemotherapeutic agents. These models and others using similar concepts are reviewed in Chapter 23. [Pg.583]

See other pages where Pharmacodynamics cell proliferation is mentioned: [Pg.185]    [Pg.286]    [Pg.13]    [Pg.402]    [Pg.463]    [Pg.253]    [Pg.273]    [Pg.568]    [Pg.88]    [Pg.193]    [Pg.754]    [Pg.315]    [Pg.133]    [Pg.348]    [Pg.1243]    [Pg.2023]    [Pg.260]    [Pg.200]   
See also in sourсe #XX -- [ Pg.583 , Pg.608 , Pg.609 , Pg.610 , Pg.611 , Pg.1012 ]



SEARCH



Cell proliferation

Pharmacodynamic

Proliferating cells

© 2024 chempedia.info